Researchers presented pooled, prospective data at ASH suggesting minimal residual disease (MRD) negativity predicts longer overall survival in acute myeloid leukemia and may serve as a surrogate endpoint in trials. The work, led by investigators at Virginia Tech’s Fralin Biomedical Research Institute, represents the largest prospective MRD dataset in AML to date and argues MRD prior to consolidation could accelerate drug approvals through the FDA’s accelerated pathway. Speakers noted MRD is already accepted as a surrogate in ALL and multiple myeloma; the new evidence aims to build a regulatory precedent in AML. The dataset focused on multiparameter flow cytometry MRD assessments and linked MRD‑negative status to subsequent survival benefit signals.